Tevogen Bio Holdings Inc. plans to expand TVGN 489 target to include older patients

From Yahoo Finance: 2025-05-25 18:19:00

Tevogen Bio Holdings Inc. plans to expand the target population for its TVGN 489 experimental medication to include patients 65 years and older. The company forecasts $1 billion in sales in the first year, with five-year projections between $18 billion to $22 billion. This decision is in response to the rise in cases of the COVID variant NB.1.8.1. TVGN 489 targets SARS-CoV-2 infections in immunocompromised patients and was created using Tevogen’s ExacTcell™ platform. The inclusion of seniors in the specialty care pipeline significantly boosts commercial potential.



Read more at Yahoo Finance: Tevogen Peports Plans to Increase the Target Population for TVGN 489